Teniposide is a cytotoxic drug used as an adjunct for chemotherapy induction in the treatment of refractory childhood acute lymphoblastic leukemia. Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity.
- Mechanism
- Curator reviewed
The mechanism of action appears to be related to the inhibition of type II topoisomerase activity since teniposide does not intercalate into DNA or bind strongly to DNA. Teniposide binds to and inhibits DNA topoisomerase II. The cytotoxic effects of teniposide are related to the relative number of double-stranded DNA breaks produced in cells, which are a reflection of the stabilization of a topoisomerase II-DNA intermediate.
- Primary indication
- Teniposide is used for the treatment of refractory acute lymphoblastic leukaemiaCurator reviewed · 1 structured indication
- Formula / weight
- C32H32O13S · 656.654 g/mol (avg)
- First approval
- Canada, 2004 · United States, 1992
- Also known as
- Epidophyllotoxin
- Code names
- EPT · PGT · VM-26
Resolves to
NRUKOCRGYNPUPR-QBPJDGROSA-NSMILES[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=C(C=C3OCOC3=C1)[C@H]2O[C@]1([H])O[C@]2([H])CO[C@H](O[C@@]2([H])[C@H](O)[C@H]1O)C1=CC=CS1What you can answer from here — as of October 01, 2026
Which drugs share a target with Teniposide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account